TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Pharmacy PHA

Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); SENATE; Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 330 (112th)

Trade (domestic/foreign) TRD

Trans-Pacific Partnership Trade Agreement

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); SENATE; White House Office; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Drug Enforcement Administration (DEA); Food & Drug Administration (FDA)

Copyright/Patent/Trademark CPT

S.27, Preserve Access to Affordable Generics Act; and S.1882, Fair & Immediate Release of Generic Drug Act

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: SENATE; Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); White House Office

Bills named: S. 1882 (112th), S. 27 (112th)

Health Issues HCR

Funding for FDA offices; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act; FDA Innovation & Safety Act; and S.2295, Patient Safety & Generic Labeling Improvement Act.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA); White House Office; Food & Drug Administration (FDA); SENATE

Bills named: S. 2295 (112th), S. 1357 (112th), S. 1882 (112th), S. 296 (112th), H.R. 4332 (112th)